Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data.
Li S , Meng XY , Maman STD , Xiao YN , Li S 
Biomed Res Int.2018 ; 2018():9057823.
PubMedで表示
Google翻訳で開く
(593view , 0users)
Full Text Sources
Medical
Miscellaneous
Refractory and relapsed multiple myeloma (RRMM) remains a clinical challenge. We compared the progression-free survival (PFS) of RRMM patients treated with lenalidomide and low dose dexamethasone plus elotuzumab or carfilzomib (ELD vs. CLD), using reconstructed individual patient data (IPD) based on two published trials reports.
PMID: 30643823 [PubMed - in process]
PMID: 30643823 [PubMed - in process]
関連論文
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma.
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
- [Review] The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
- Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.